人工智能应用于食管癌临床诊疗的专家共识

2021-08-25 中国医院协会介入医学中心专会 中华介入放射学电子杂志

一、我国食管癌的诊疗现状食管癌居中国恶性肿瘤发病率第六位,死亡率第四位,是我国常发、危害重大的疾病[1]。全球每年新增食管癌患者近50%来自于中国,90%为食管鳞癌[2]。

中文标题:

人工智能应用于食管癌临床诊疗的专家共识

发布日期:

2021-08-25

简要介绍:

一、我国食管癌的诊疗现状食管癌居中国恶性肿瘤发病率第六位,死亡率第四位,是我国常发、危害重大的疾病[1]。全球每年新增食管癌患者近50%来自于中国,90%为食管鳞癌[2]。食管癌具有高浸润性和淋巴结跳跃性转移的特点,早期症状隐匿难以发现,中晚期食管梗阻、病灶浸润和转移严重影响患者生活质量及生存预后。食管癌的主要治疗方法如手术、化疗、放疗及靶向治疗等已在我国广泛推广,但我国患者的五年生存率仅为30.3%,是我国必须自主攻克的重大疾病[3-4]。

相关资料下载:
[AttachmentFileName(sort=1, fileName=人工智能应用于食管癌临床诊疗的专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f96591c002235826, title=人工智能应用于食管癌临床诊疗的专家共识, enTitle=, guiderFrom=中华介入放射学电子杂志, authorId=0, author=, summary=一、我国食管癌的诊疗现状食管癌居中国恶性肿瘤发病率第六位,死亡率第四位,是我国常发、危害重大的疾病[1]。全球每年新增食管癌患者近50%来自于中国,90%为食管鳞癌[2]。, cover=https://img.medsci.cn/20211025/1635140959382_1608702.jpg, journalId=0, articlesId=null, associationId=2041, associationName=中国医院协会介入医学中心专会, associationIntro=中国医院协会介入医学中心专会, copyright=0, guiderPublishedTime=Wed Aug 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">一、我国食管癌的诊疗现状食管癌居中国恶性肿瘤发病率第六位,死亡率第四位,是我国常发、危害重大的疾病[1]。全球每年新增食管癌患者近50%来自于中国,90%为食管鳞癌[2]。食管癌具有高浸润性和淋巴结跳跃性转移的特点,早期症状隐匿难以发现,中晚期食管梗阻、病灶浸润和转移严重影响患者生活质量及生存预后。食管癌的主要治疗方法如手术、化疗、放疗及靶向治疗等已在我国广泛推广,但我国患者的五年生存率仅为30.3%,是我国必须自主攻克的重大疾病[3-4]。</span></p>, tagList=[TagDto(tagId=751, tagName=食管癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=72, categoryName=人工智能, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=751, guiderKeyword=食管癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2541, appHits=79, showAppHits=0, pcHits=291, showPcHits=2462, likes=0, shares=7, comments=3, approvalStatus=1, publishedTime=Mon Oct 25 16:24:48 CST 2021, publishedTimeString=2021-08-25, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Mon Oct 25 16:06:55 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Tue Jan 02 22:41:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=人工智能应用于食管癌临床诊疗的专家共识.pdf)])
人工智能应用于食管癌临床诊疗的专家共识.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1179147, encodeId=efe411e91474f, content=非常好非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/19/3dac6c023a2227430f582458b92baf75.jpg, createdBy=a0242124870, createdName=1881fb789am, createdTime=Fri Dec 31 10:23:29 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065255, encodeId=76a310652559f, content=非常好非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Sat Oct 30 13:07:05 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064041, encodeId=c71e106404127, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 11:59:14 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-12-31 1881fb789am

    非常好非常好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1179147, encodeId=efe411e91474f, content=非常好非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/19/3dac6c023a2227430f582458b92baf75.jpg, createdBy=a0242124870, createdName=1881fb789am, createdTime=Fri Dec 31 10:23:29 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065255, encodeId=76a310652559f, content=非常好非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Sat Oct 30 13:07:05 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064041, encodeId=c71e106404127, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 11:59:14 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-10-30 ms6000001387765207

    非常好非常好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1179147, encodeId=efe411e91474f, content=非常好非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/19/3dac6c023a2227430f582458b92baf75.jpg, createdBy=a0242124870, createdName=1881fb789am, createdTime=Fri Dec 31 10:23:29 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065255, encodeId=76a310652559f, content=非常好非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Sat Oct 30 13:07:05 CST 2021, time=2021-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064041, encodeId=c71e106404127, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 11:59:14 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-10-26 ms6000001387765207

    good

    0

拓展阅读

2010ESMO临床实践指南:食管癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

食管癌规范化诊治指南

中国抗癌协会食管癌专业委员会(Chinese Society of Esophagenal Cancer, Chinese Anti-Cancer Association) · 2011-04-01

2011 AUGIS/BSG指南:食管癌与胃癌的处理

大不列颠爱尔兰上消化道外科医师协会(AUGIS,Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland) · 2011-07-24

2012 ASGE 内镜在Barrett食管及其他食管癌前病变中的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2012-12-01

2013 ASEG内镜在食管癌评估与治疗方面的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2013-03-01

2013 STS指南:食管癌患者的诊断与分期

美国胸外科医师学会(STS,Society of Thoracic Surgeons) · 2013-06-07